Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3 OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND YOUNG CHILDREN IN CHINA WHO ARE NAIVE TO PNEUMOCOCCAL VACCINATION

NCT03574389 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03574389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03574389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3 OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND YOUNG CHILDREN IN CHINA WHO ARE NAIVE TO PNEUMOCOCCAL VACCINATION
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
June 23, 2018
Completion date
October 13, 2023
Enrollment
936 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal conjugate vaccine, pneumococcal infections